Lung cancer

Lung cancer is a group of malignant tumors that originate in the lungs, usually in the cells lining the airways or air sacs. It is distinguished from cancers that begin elsewhere and spread to the lungs. The principal clinical categories are non-small-cell lung cancer, which includes adenocarcinoma and squamous-cell carcinoma, and small-cell lung cancer; these differ in their biology, patterns of spread, and treatment. (cancer.gov)

Lung cancer is a major global public health problem. An estimated 2.5 million new cases and 1.8 million deaths occurred worldwide in 2022, making it the leading cause of cancer death. Tobacco smoking is its principal preventable cause, but lung cancer also occurs in people who have never smoked; environmental and occupational exposures contribute to risk. Early disease may cause few symptoms, and many cases are diagnosed after substantial spread. (who.int)

Understanding lung cancer requires integrating its tissue classification, molecular characteristics, and anatomical stage. Imaging and biopsy establish the diagnosis and extent of disease, while biomarker testing can identify features relevant to treatment. Management may involve surgery, radiation therapy, chemotherapy, targeted medicines, and cancer immunotherapy, together with supportive and palliative care. Prevention and evidence-based screening complement these approaches. (cancer.org)

Definition and anatomical origins

Lung cancer is a primary malignancy arising in the tissues of the lung, usually in the epithelial cells lining its airways or distal air spaces. “Primary” identifies the organ in which the malignancy originated, not every organ in which malignant tissue is subsequently found. A breast cancer that spreads to the lung, for example, remains metastatic breast cancer rather than becoming lung cancer. Conversely, a lung cancer that spreads beyond the chest retains its pulmonary origin. The principal epithelial malignancies are grouped as small-cell and non-small-cell lung cancer; their detailed classification depends on microscopic pathology, rather than location alone. (cancer.gov)

Primary pulmonary malignancies must also be distinguished from cancers originating in the pleura. The visceral pleura covers the lung surface, while the parietal pleura lines the chest wall; a narrow, fluid-containing space separates them. Pleural mesothelioma arises in this covering tissue and is a different malignancy from a carcinoma originating within the lung. Lung carcinoma can nevertheless invade the pleura or produce metastatic pleural deposits. Thus, the presence of cancer at the lung surface or in pleural fluid does not, by itself, identify the tissue of origin. (training.seer.cancer.gov)

The airway tree provides an anatomical continuum of potential origins. The trachea divides into right and left main bronchi, which branch into lobar and segmental bronchi and progressively smaller bronchioles. The right lung has three lobes and the left two. Bronchi contain cartilage-supported walls; cartilage disappears in the smaller bronchioles. Along this branching system, the lining changes from predominantly ciliated columnar epithelium to simpler cuboidal and squamous epithelium distally. Alveolar ducts and alveoli form the gas-exchanging region, where thin epithelial walls separate inhaled air from capillary blood. These differences in epithelial structure help explain why pulmonary carcinomas are not uniformly distributed throughout the organ. (training.seer.cancer.gov)

A central tumor lies near the major bronchi and pulmonary hilum, the medial gateway through which airways, vessels, lymphatics, and nerves pass. Squamous-cell carcinoma commonly originates near a central bronchus, whereas adenocarcinoma more often originates in peripheral lung tissue, including the distal respiratory epithelium. These are anatomical tendencies, not rules defining a tumor’s microscopic type. The traditional term bronchogenic carcinoma emphasizes an airway epithelial origin, but its clinical scope includes both small-cell and non-small-cell carcinomas, rather than only tumors visibly arising in a large bronchus. Consequently, the term should not be interpreted as excluding peripheral pulmonary carcinomas or as specifying one histological subtype. (training.seer.cancer.gov)

Regional lymphatic drainage connects the lung to intrapulmonary, hilar, and mediastinal lymph nodes. Intrapulmonary groups accompany subsegmental, segmental, and lobar bronchi; interlobar nodes lie between lobar airways, and hilar nodes lie at the lung root. Mediastinal groups include subcarinal nodes beneath the tracheal bifurcation and paratracheal nodes alongside the trachea. The International Association for the Study of Lung Cancer anatomical map organizes regional nodes into 14 station groups, also including a low cervical–supraclavicular group. This distribution supplies the anatomical framework for recording regional nodal involvement, distinct from the location of the primary tumor itself. (training.seer.cancer.gov)

Histological classification

The 2021 fifth edition of the World Health Organization classification organizes lung tumors by their microscopic architecture, cellular features, and differentiation. Non-small-cell lung cancer (NSCLC) is an umbrella category rather than a single histological diagnosis; its principal types are adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. Adenocarcinoma shows glandular differentiation or mucin production. Invasive nonmucinous adenocarcinomas commonly contain several growth patterns, recorded by their proportions and predominant component: lepidic growth along existing alveolar walls, acinar glands, papillary structures with fibrovascular cores, micropapillary clusters without such cores, and solid sheets. Invasive mucinous adenocarcinoma is a distinct type, typically composed of mucus-rich columnar or goblet-like cells. (publications.iarc.fr)

Squamous-cell carcinoma is characterized by keratinization or intercellular bridges; nonkeratinizing and basaloid forms are also recognized. Large-cell carcinoma is an undifferentiated carcinoma lacking demonstrable glandular, squamous, or neuroendocrine differentiation after adequate examination. It is a diagnosis of exclusion requiring a thoroughly sampled resection, not simply a label for any tumor with large cells. Less common NSCLC types include adenosquamous carcinoma, with adenocarcinoma and squamous components each occupying at least 10% of the tumor; sarcomatoid carcinomas, which may contain spindle or giant cells; and salivary-gland-type carcinomas, including mucoepidermoid and adenoid cystic carcinoma. (pmc.ncbi.nlm.nih.gov)

Small-cell lung carcinoma consists of densely packed small cells with scant cytoplasm, indistinct cell boundaries, finely granular chromatin, and absent or inconspicuous nucleoli. Nuclear molding—the conformity of adjacent nuclei to one another—is characteristic, and mitotic activity is high. Combined small-cell carcinoma contains a recognizable small-cell component together with another carcinoma component, such as adenocarcinoma or squamous-cell carcinoma. No minimum proportion of those additional components is required; when the additional component is large-cell neuroendocrine carcinoma, it must constitute at least 10%. The combined designation describes different histologies within one tumor, rather than separate primary cancers. (cancer.gov)

Pulmonary neuroendocrine neoplasms comprise well-differentiated typical and atypical carcinoids and poorly differentiated small-cell and large-cell neuroendocrine carcinomas. Carcinoids usually form orderly nests or trabeculae of relatively uniform cells with finely stippled chromatin. Typical carcinoid has fewer than two mitoses per $2\,\mathrm{mm}^{2}$ and no necrosis; atypical carcinoid has 2–10 mitoses per $2\,\mathrm{mm}^{2}$, necrosis, or both. These correspond to low- and intermediate-grade tumors, respectively, with atypical carcinoids having a greater propensity for recurrence and metastasis. Large-cell neuroendocrine carcinoma combines neuroendocrine architecture and marker expression with larger cells, more abundant cytoplasm or prominent nucleoli, high mitotic activity, and commonly extensive necrosis. It and small-cell carcinoma are aggressive high-grade carcinomas; the four categories do not imply an obligatory progression from carcinoid to carcinoma. (nature.com)

Preinvasive lesions include atypical adenomatous hyperplasia, adenocarcinoma in situ, and squamous-cell carcinoma in situ. Adenocarcinoma in situ is a tumor no larger than 3 cm with purely lepidic growth and no invasion. Minimally invasive adenocarcinoma is also no larger than 3 cm, but has predominantly lepidic growth and an invasive component measuring no more than 5 mm; vascular or pleural invasion and tumor necrosis exclude this diagnosis. Establishing either category requires examination of the entire lesion, because a small biopsy cannot exclude unsampled invasion. The 2011 multidisciplinary classification led by William D. Travis, Elisabeth Brambilla, and Masayuki Noguchi introduced these distinctions and discontinued “bronchioloalveolar carcinoma,” which had encompassed biologically different lesions. (pmc.ncbi.nlm.nih.gov)

Histological grade describes differentiation and architecture, rather than anatomical extent. The IASLC grading system proposed in 2020 for invasive nonmucinous adenocarcinoma assigns grade 1 to lepidic-predominant tumors and grade 2 to acinar- or papillary-predominant tumors, provided high-grade patterns occupy less than 20%. Any tumor containing at least 20% solid, micropapillary, or complex glandular patterns is grade 3. Thus, a papillary-predominant tumor with 25% solid growth is classified as poorly differentiated despite its predominant pattern. This system is not a universal grading scheme for every lung carcinoma. (pmc.ncbi.nlm.nih.gov)

Global epidemiology and disease burden

The International Agency for Research on Cancer (IARC), the cancer research agency of the World Health Organization, estimated approximately 2.5 million new lung cancer cases and 1.8 million deaths worldwide in 2022. In the GLOBOCAN 2022 dataset, lung cancer accounted for 12.4% of newly diagnosed cancers and 18.7% of cancer deaths, making it the most frequently diagnosed cancer and the leading cause of cancer death when both sexes were combined. These figures describe the estimation year 2022, not the publication year of the principal report, which appeared in April 2024. The dataset covered 185 countries or territories and used population-based cancer registries, national vital statistics, and estimation methods suited to the available local data. Its figures are therefore estimates rather than a complete worldwide enumeration; their uncertainty depends partly on the coverage, timeliness, and quality of the underlying records. (iarc.who.int)

Comparisons between populations use age-standardized incidence rates and mortality rates, expressed per 100,000 people per year and weighted to a common world standard population. This removes differences attributable to population age structure, rather than to differences in disease occurrence. In 2022, the global age-standardized incidence rate was 23.6 and the mortality rate was 16.8. Male incidence was 32.1, compared with 16.2 in females; corresponding mortality rates were 24.8 and 9.8. Approximately 1.57 million new cases occurred in males and 0.91 million in females, while deaths numbered approximately 1.23 million and 0.58 million, respectively. (dr2pp.oss.ns-svc.cn)

Regional differences persisted after age standardization. Male incidence rates in 2022 were 51.4 in Eastern Asia and 49.8 in Eastern Europe, compared with 33.8 in Northern America and 2.5 in Western Africa. Among females, Northern America had an incidence rate of 30.4, Eastern Asia 28.4, Eastern Europe 11.9, and Western Africa 1.5. Thus, the male–female incidence gap was much smaller in Northern America than in Eastern Europe. Mortality also showed substantial sex differences: Eastern European rates were 39.5 in males and 9.1 in females. These standardized rates describe population-level occurrence; absolute case numbers additionally depend on population size. (dr2pp.oss.ns-svc.cn)

Age-specific measures, rather than age-standardized rates, show how disease burden varies across the lifespan. Lung cancer is concentrated in older adults. As a documented national example, United States SEER registry data for diagnoses in 2019–2023 recorded a median age at diagnosis of 71 years: 36.4% of cases occurred at ages 65–74 and 28.4% at ages 75–84, whereas 1.1% occurred before age 45. United States mortality records for 2020–2024 showed a median age at death of 73 years. These age distributions are specific to the recorded population and periods, rather than global estimates. (seer.cancer.gov)

Temporal patterns closely follow the histories of tobacco use in successive birth cohorts. In countries such as the United Kingdom and United States, male lung cancer rates rose, peaked, and declined after corresponding changes in smoking prevalence, with an approximately 20–25-year lag. Women generally took up widespread smoking later, producing later peaks or continuing increases in many populations while male rates declined. IARC’s 2025 analysis described generally declining male incidence in most countries over the preceding 30–40 years, alongside a tendency for female rates to rise. These trajectories are not universal: in United States data, age-adjusted incidence fell by an average of 1.9% annually during 2014–2023, and mortality by 4.1% annually during 2015–2024. (dr2pp.oss.ns-svc.cn)

People who have never smoked constitute a distinct component of the burden. The US Centers for Disease Control and Prevention estimates that 10–20% of US lung cancers occur in people who never smoked or smoked fewer than 100 cigarettes during their lifetime. The proportion is higher in some populations, notably Eastern Asian women, among whom smoking prevalence is comparatively low; environmental exposures, including air pollution and household solid-fuel combustion, contribute to these patterns. Adenocarcinoma accounts for approximately 50–60% of lung cancers among never-smokers in the CDC’s description. A rising proportion of cases among never-smokers does not, by itself, establish rising incidence in that group: the proportion can also increase as smoking-associated disease declines. (cdc.gov)

Causes and risk factors

Tobacco smoking is the predominant established cause of lung cancer. Tobacco smoke contains carcinogens, including tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons, that can damage DNA. Risk increases with both smoking duration and the number of cigarettes smoked daily; the National Cancer Institute estimates that current smokers have approximately 20 times the risk of nonsmokers. Cumulative exposure is commonly expressed in pack-years, calculated as packs smoked per day multiplied by years smoked: one pack daily for 30 years represents 30 pack-years. This measure records cumulative consumption, while duration and daily intensity remain distinct components of exposure. Secondhand smoke—from burning tobacco and smoke exhaled by smokers—is also an established cause. Nonsmokers exposed to it have approximately 20% greater risk than unexposed nonsmokers; this is a relative increase, not a 20-percentage-point increase in absolute risk. (cancer.gov)

Radon is a naturally occurring radioactive gas produced by uranium decay in rocks and soil. It can enter buildings from the ground and accumulate indoors. Inhaled radioactive decay products deposit in the airways and irradiate nearby cells, damaging DNA. Evidence comes from highly exposed underground miners and residential studies in Europe, North America, and China. The World Health Organization estimates that lung cancer risk increases by about 16% for each $100\ \mathrm{Bq/m^3}$ increase in long-term average radon concentration. Radon causes disease in people who have never smoked, but its interaction with smoking produces a substantially greater absolute burden among smokers. (who.int)

Asbestos causes lung cancer independently of its role in mesothelioma, a malignancy of the membranes lining the chest or abdomen. Exposure has occurred in insulation manufacture, construction, shipbuilding, and the disturbance of asbestos-containing materials during repair or demolition. Risk depends on exposure dose, duration, and fiber characteristics; asbestos-related disease may appear decades after exposure. Combined asbestos exposure and smoking produce a lung cancer risk greater than the sum of their separate effects. Other established occupational lung carcinogens include arsenic, nickel compounds, chromium compounds, beryllium, cadmium, and tar or soot. Diesel engine exhaust is also a cause: IARC’s evaluation, published in its 2013 monograph, drew partly on occupational studies of underground miners and other exposed workers. These exposures can cause lung cancer without tobacco smoking. (cancer.gov)

Outdoor air pollution and its particulate component were classified by IARC as carcinogenic to humans in 2013, on evidence that they cause lung cancer. Indoor combustion requires distinctions between fuels: emissions from household coal combustion were classified as carcinogenic to humans in 2006, whereas emissions from household biomass combustion, including wood and crop residues, were classified as probably carcinogenic. The latter designation reflects a less conclusive evidence base, rather than proof that all solid fuels carry identical risks. Household combustion exposures arise particularly during cooking and heating and vary with fuel, combustion conditions, and ventilation. (who.int)

Older age is associated with greater risk, especially alongside a substantial smoking history. A family history is also associated with risk: a meta-analysis summarized by the National Cancer Institute found approximately twice the risk among people with affected relatives. Familial clustering does not by itself establish inherited causation, because relatives may share smoking habits and secondhand exposure. Nevertheless, specific inherited susceptibility exists: a prospective study of 77 people from 39 families documented a familial syndrome involving pathogenic germline variants in the EGFR gene, principally T790M. Such inherited variants are distinct from mutations acquired within a tumor. Previous thoracic radiotherapy, including treatment for breast cancer or Hodgkin lymphoma, is an established radiation-related risk; risk increases with radiation dose and is amplified by cigarette smoking. (cancer.gov)

Carcinogenesis and molecular biology

Tobacco carcinogens can damage DNA through the formation of DNA adducts: chemically reactive metabolites bind covalently to DNA bases. If these lesions escape DNA repair and are copied incorrectly during replication, they become permanent mutations. In 2016, Ludmil Alexandrov and colleagues analysed 5,243 cancer genomes and identified several smoking-associated mutational signatures. One, now designated SBS4, is enriched in cytosine-to-adenine substitutions and resembles the pattern produced experimentally by benzo[a]pyrene, a tobacco-smoke carcinogen. Such signatures record mutational processes rather than identifying the cause of every individual mutation; endogenous processes also contribute to lung carcinogenesis. (pmc.ncbi.nlm.nih.gov)

Tumour development involves selection among populations of altered cells. A driver alteration increases a cell’s capacity to survive or reproduce, allowing its descendants to expand; passenger mutations accompany this expansion without necessarily providing an advantage. Changes affecting growth signals, cell-cycle checkpoints, DNA repair and apoptosis can cooperate to overcome normal tissue constraints. Invasive cancer additionally acquires the capacity to penetrate surrounding tissue rather than remaining confined to its epithelial compartment. Tumour-suppressor disruption differs from oncogene activation: loss of TP53 compromises responses to cellular damage, while loss of RB1 removes an important restraint on cell-cycle progression. Julie George and colleagues’ 2015 genomic study of 110 small-cell lung cancers found inactivation of both copies of TP53 and RB1 in nearly all tumours examined. (cancer.gov)

EGFR and KRAS illustrate two routes to abnormal growth signalling. EGFR encodes a receptor tyrosine kinase; common activating alterations include in-frame deletions in exon 19 and L858R, which substitutes arginine for leucine at amino-acid position 858. These alterations increase kinase activity and downstream signalling through pathways including MAPK and PI3K–AKT. KRAS encodes a small GTPase that switches between active, GTP-bound and inactive, GDP-bound states. Mutations such as G12C impair regulation of GTP hydrolysis and favour growth-promoting signalling, although G12C retains nucleotide cycling rather than being permanently locked in an active state. The Cancer Genome Atlas’s 2014 analysis of 230 resected lung adenocarcinomas reported KRAS mutations in 33% and EGFR mutations in 14%; these cohort-specific frequencies are not universal population estimates. Such driver mutations are generally acquired, or somatic, alterations in the tumour lineage, distinct from inherited germline variants present throughout the body. A tumour-sequencing result alone does not establish inheritance. (doi.org)

The originating cell and the eventual tumour phenotype are not necessarily identical. In a 2022 lineage-tracing study, Eml4–Alk-driven mouse adenocarcinomas arose from both alveolar type II cells and airway club cells. Club-derived tumours underwent an epigenetic switch and acquired an alveolar type II-like phenotype. This demonstrates cellular plasticity in that experimental system, not a settled account of the origin of every human adenocarcinoma. Human tumours also evolve into genetically distinct subclones. Alexander Frankell and colleagues’ 2023 TRACERx analysis examined 1,644 tumour regions from 421 patients with non-small-cell lung cancer and documented extensive branching evolution and selection of subclonal driver alterations. Consequently, a single tissue sample need not represent the complete genetic composition of a tumour. (nature.com)

The tumour microenvironment also imposes selective pressures. Mutated proteins can generate neoantigens recognised by T cells, but emerging cancer populations may evade recognition by losing antigen-bearing genomic regions or reducing neoantigen expression. Rachel Rosenthal and colleagues documented these mechanisms in the 2019 TRACERx study of immune escape. Tumour cells can also inhibit immune activity through PD-L1 binding to PD-1 on T cells, engaging an immune checkpoint that normally limits excessive immune responses. These interactions make tumour evolution dependent not only on cancer-cell mutations but also on the surrounding immune context; the resulting biology varies between tumours and between regions of the same tumour. (nature.com)

Symptoms, local effects, and systemic manifestations

Lung cancer may be asymptomatic, and the absence of symptoms does not establish that disease is confined to the lung. Common manifestations include a persistent or worsening cough, hemoptysis—blood or blood-streaked sputum—breathlessness, chest pain, reduced appetite, unexplained weight loss, and fatigue. Chest pain may worsen with deep inspiration or coughing. These symptoms are not specific to malignancy and also occur in nonmalignant respiratory disorders. Their distribution reflects the tumor’s location, its effects on surrounding structures, and systemic disturbances rather than a single characteristic presentation. (cancer.org)

A tumor growing within a bronchus, or compressing it externally, can restrict airflow and cause wheezing or breathlessness. Obstruction may produce collapse of the lung beyond the blockage, termed atelectasis, and postobstructive inflammation or pneumonia; infections may persist or recur. Pleural effusion is fluid accumulation between the lung and chest wall. In cancer, it can result from pleural tumor deposits, increased vascular permeability, or impaired drainage through the lymphatic system. The fluid restricts lung expansion and may cause breathlessness, cough, and chest discomfort. Not every effusion in a person with lung cancer contains malignant cells: associated conditions, including atelectasis or lymph-node involvement, can also produce fluid accumulation. (cancer.gov)

Compression or invasion of the superior vena cava impedes venous return from the upper body, producing facial, neck, and arm swelling, distended superficial veins, and breathlessness. Severe obstruction can cause headache or altered consciousness. Compression of laryngeal nerves may cause hoarseness, while involvement of the esophagus can cause difficulty swallowing. Apical cancers, often called Pancoast tumors, can produce severe shoulder pain and affect sympathetic nerves supplying the face and eye. The resulting Horner syndrome comprises a drooping upper eyelid, a constricted pupil, and reduced sweating on the affected side. These are local anatomical effects, distinct from remote paraneoplastic disorders. (cancer.gov)

Paraneoplastic syndromes arise through tumor-derived substances or immune responses rather than direct invasion of the affected organ, and may precede recognition of the lung tumor. Hypercalcemia can occur when tumor cells release parathyroid hormone-related peptide, which acts on bone and kidneys to raise blood calcium. Manifestations include thirst, frequent urination, constipation, weakness, and confusion. In the syndrome of inappropriate antidiuretic hormone secretion (SIADH), particularly associated with small-cell carcinoma, ectopic vasopressin production causes renal water retention and dilutional hyponatremia. Symptoms range from nausea and fatigue to confusion, seizures, or coma. William B. Schwartz and colleagues’ 1960 metabolic study described these disturbances in a third patient, following their earlier report of two patients with bronchogenic carcinoma; persistently concentrated urine despite hypotonic blood supported inappropriate antidiuretic activity. (cancer.org)

Lambert–Eaton myasthenic syndrome is an immune-mediated disorder of neuromuscular transmission associated especially with small-cell lung cancer, although it also occurs without cancer. Antibodies against presynaptic voltage-gated calcium channels impair neurotransmitter release. Characteristic manifestations include proximal leg weakness, difficulty rising from a chair or climbing stairs, reduced reflexes, and autonomic disturbances such as dry mouth; strength may briefly improve after initial exercise. A prospective study published in 2010 examined 63 patients with confirmed small-cell lung cancer: five had elevated calcium-channel antibodies, but only two, approximately 3%, had clinical and electrophysiological evidence of Lambert–Eaton syndrome. This distinction demonstrates that antibody detection alone is not equivalent to symptomatic neuromuscular disease. (pmc.ncbi.nlm.nih.gov)

Diagnostic investigation and differential diagnosis

Chest radiography may reveal a mass, lobar collapse, persistent consolidation, or pleural effusion, but computed tomography (CT) detects smaller lesions and defines their relationship to airways, blood vessels, pleura, and regional lymph nodes more clearly. Diagnostic CT characterizes an abnormality; it does not, by itself, establish that the lesion is malignant. Contrast-enhanced CT also helps select a sampling site. The United Kingdom’s NICE guideline, published in 2019 and updated in 2024, specifies imaging of the chest, liver, adrenal glands, and lower neck before biopsy. Thus, detecting a suspicious lesion and confirming cancer are separate steps: pathological confirmation depends on identifying malignant cells in a tissue or cytological specimen. (cancer.org)

The sampling method depends on lesion location, accessibility, procedural risk, and whether a specimen can establish both diagnosis and disease extent. Flexible bronchoscopy permits direct examination of the larger airways and biopsy of visible central tumors. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) uses ultrasound to identify structures beyond the airway wall and guide a needle into mediastinal or hilar lymph nodes; a positive nodal sample may provide diagnosis and staging information in the same procedure. Peripheral lesions can be sampled by CT-guided percutaneous biopsy, in which a needle passes through the chest wall. Fine-needle aspiration primarily supplies cells, whereas core biopsy preserves tissue architecture. Pneumothorax and bleeding are important procedural limitations. Small or difficult-to-reach lesions may yield insufficient material, and thoracoscopic sampling is sometimes required when less invasive methods are inconclusive. (cancer.org)

When pleural fluid is present, thoracentesis obtains fluid for cytological examination. Malignant cells can establish pleural involvement, but an effusion may instead result from infection, heart failure, or another nonmalignant process. Negative cytology does not exclude pleural malignancy, because diagnostic sensitivity varies with tumor type and the material obtained. The 2023 British Thoracic Society guideline specifies an initial cytology sample of 25–50 mL and processing by direct smear and cell-block preparation; it also recognizes that negative results may require further investigation, including image-guided or thoracoscopic pleural biopsy. Sputum cytology has a more restricted role, particularly for central lesions when invasive sampling cannot be undertaken. (thorax.bmj.com)

In pathological examination, tissue architecture and cellular morphology are assessed under the microscope. Immunohistochemistry uses antibodies to detect proteins that support classification, especially in poorly differentiated tumors or small specimens. The IASLC Pathology Committee’s 2019 recommendations identify TTF-1 and p40 as a useful limited panel for distinguishing adenocarcinoma from squamous-cell carcinoma when morphology alone is insufficient. TTF-1 supports pulmonary adenocarcinoma in the appropriate context, whereas strong, sufficiently extensive nuclear p40 staining supports squamous differentiation. Neither marker independently proves the anatomical origin of every tumor. Distinguishing a primary lung carcinoma from a metastasis requires integration of imaging, previous cancer history, morphology, and selected additional stains, ideally with comparison to the earlier tumor specimen. Limiting unnecessary stains preserves material for subsequent predictive biomarker testing. (pmc.ncbi.nlm.nih.gov)

The differential diagnosis of a pulmonary nodule includes infectious granulomas, including those associated with tuberculosis, benign tumors such as hamartomas, intrapulmonary lymph nodes, and metastatic malignancy. Certain CT findings strongly support benignity: the 2015 British Thoracic Society nodule guideline identifies diffuse, central, laminated, or “popcorn” calcification and macroscopic fat as characteristic benign features. Other lesions remain indeterminate and require assessment of clinical risk, interval growth, or sampling. A nondiagnostic biopsy—containing normal lung, necrotic material, or too few representative cells—is not equivalent to a benign diagnosis. Negative biopsy findings must be interpreted against the pretest probability of malignancy; persistent radiological suspicion can lead to repeat sampling or surgical biopsy rather than acceptance of the initial result as exclusion of cancer. (doi.org)

Molecular and predictive biomarker testing

A biomarker is diagnostic when it helps identify or classify disease, prognostic when it provides information about the likely disease course, and predictive when it identifies a greater or lesser likelihood of benefit from a particular treatment. These functions are not interchangeable: an alteration associated with aggressive disease does not necessarily identify an effective drug. In non-small-cell lung cancer (NSCLC), especially adenocarcinoma, tumor profiling complements pathological diagnosis by identifying molecular features relevant to treatment selection. Testing tumor DNA principally examines acquired, somatic alterations; it is distinct from testing inherited cancer susceptibility, although some tumor findings require separate testing of nonmalignant cells to establish whether they are inherited. (cancer.gov)

Tissue-based testing uses material from a biopsy, surgical specimen, or adequately preserved cytology preparation. Laboratories assess cancer-cell content and specimen quality because insufficient tumor material can make testing unsuccessful or reduce sensitivity. Multigene panels using next-generation sequencing examine many targets in parallel, rather than consuming material through successive single-gene assays. The 2018 joint guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology preferred multiplex sequencing panels over multiple single-gene tests. Depending on the target, laboratories also use polymerase chain reaction, fluorescence in situ hybridization, or validated immunohistochemistry; ALK protein testing, for example, can serve as an alternative to ALK rearrangement testing by fluorescence in situ hybridization. (cap.org)

Actionable findings are defined by the specific alteration, not simply by the presence of a change in a named gene. Examples include EGFR exon 19 deletions and exon 21 L858R substitutions; ALK and ROS1 rearrangements; BRAF V600E; KRAS G12C; MET alterations causing exon 14 skipping; RET fusions; and fusions involving NTRK genes. These abnormalities can identify candidates for corresponding molecularly targeted treatments in defined clinical settings. EGFR exon 20 insertions form a distinct treatment category from common sensitizing EGFR variants. Likewise, evidence for targeting KRAS G12C cannot be generalized to every KRAS mutation, and an NTRK sequence variant is not equivalent to an oncogenic NTRK fusion. Stage, previous treatment, and the evidence supporting the particular drug–alteration pairing remain relevant to interpretation. (cancer.gov)

PD-L1 testing measures protein expression rather than a genomic driver. PD-L1 is a ligand for the PD-1 immune checkpoint, and its expression helps select some immunotherapy regimens. Immunohistochemical assays stain tumor sections with antibodies; the 22C3 assay reports a tumor proportion score (TPS), the percentage of viable tumor cells showing partial or complete membrane staining. Its NSCLC categories include expression at TPS ≥1% and high expression at TPS ≥50%, although the applicable threshold depends on the treatment indication. PD-L1 does not replace genomic profiling: some immunotherapy indications exclude EGFR- or ALK-driven tumors, while certain chemotherapy–immunotherapy combinations have demonstrated benefit irrespective of PD-L1 expression. Thus, absent staining does not exclude benefit from every immunotherapy-containing regimen. (accessdata.fda.gov)

A liquid biopsy can analyze circulating tumor DNA (ctDNA), tumor-derived fragments within the cell-free DNA in plasma. It provides an additional route to molecular profiling when tissue is insufficient or difficult to obtain and can also investigate molecular changes after progression. However, tumors release variable amounts of DNA, and plasma may not represent every tumor population; alterations below the assay’s detection limit can therefore produce false-negative results. A negative plasma result does not establish that the tumor lacks an actionable alteration, so tissue testing remains complementary. Plasma genotyping also does not provide the microscopic information needed for histological classification. Detection itself does not guarantee treatment benefit: benign variants and variants of uncertain significance are not established treatment-selection markers, and even a validated biomarker indicates a probability of benefit rather than a certain response. (iaslc.org)

Staging and patterns of spread

Lung cancer spreads by direct invasion, lymphatic dissemination, and metastasis through the bloodstream. Direct extension may involve the visceral pleura, chest wall, diaphragm, mediastinum, or major vessels. Tumor cells entering the lymphatic system can establish deposits in intrapulmonary and hilar lymph nodes, mediastinal nodes, and more distant nodal groups; involvement does not invariably follow a sequential pathway. Blood-borne dissemination commonly affects the brain, bone, liver, and adrenal glands. Spread onto pleural or pericardial surfaces can produce malignant nodules or effusions. These deposits remain lung cancer rather than becoming primary cancers of the affected organ. (cancer.gov)

The TNM classification describes the primary tumor (T), regional lymph-node involvement (N), and metastases (M). The ninth edition for lung cancer was introduced in 2025, incorporating revisions developed through the International Association for the Study of Lung Cancer (IASLC) staging project. T categories retain the preceding edition’s principal criteria: T1 tumors measure no more than 3 cm, T2 tumors generally measure more than 3 to 5 cm, T3 more than 5 to 7 cm, and T4 more than 7 cm; specified invasive features can assign a higher category regardless of size. For example, chest-wall invasion is T3, whereas invasion of the heart or major vessels is T4. Separate tumor nodules attributable to the same cancer are T3 in the same lobe and T4 in another ipsilateral lobe. (iaslc.org)

N0 denotes absence of regional nodal metastases; N1 involves ipsilateral intrapulmonary, peribronchial, or hilar nodes. N2 involves ipsilateral mediastinal or subcarinal nodes and, in the ninth edition, is divided into N2a, involving one nodal station, and N2b, involving multiple stations—not simply different numbers of positive nodes. N3 includes contralateral mediastinal or hilar nodes and scalene or supraclavicular nodes on either side. M1a comprises contralateral pulmonary tumor nodules, pleural or pericardial nodules, or malignant pleural or pericardial effusions; M1b denotes one extrathoracic metastasis. Multiple extrathoracic metastases are subdivided into M1c1 when confined to one organ system and M1c2 when involving several. (education.iaslc.org)

TNM combinations form stage groups: stage 0 represents carcinoma in situ, stages I–III describe specified combinations without distant metastasis, and stage IV denotes M1 disease. M1a and M1b are stage IVA; M1c1 and M1c2 are stage IVB. Ninth-edition examples include T1N1M0 as IIA, T1N2aM0 as IIB, and T1N2bM0 as IIIA, illustrating why nodal location and distribution matter alongside tumor size. Clinical stage, prefixed c, uses pretreatment examination, imaging, and biopsy findings. Pathological stage, prefixed p, adds examination of the resected tumor and lymph nodes and may reveal disease not apparent clinically. A needle biopsy confirming cancer does not by itself constitute complete pathological staging. (pubmed.ncbi.nlm.nih.gov)

Staging investigations combine anatomical imaging with assessment of otherwise occult spread. Chest and upper-abdominal CT define local relationships and potential metastatic lesions. FDG PET–CT evaluates metabolically active nodal and distant deposits, but inflammation can cause false-positive uptake and small deposits can escape detection. Brain MRI evaluates intracranial spread; FDG-PET cannot reliably replace it because normal brain tissue takes up the tracer. Suspicious mediastinal nodes can undergo sampling by endobronchial ultrasound-guided needle aspiration, endoscopic ultrasound, or mediastinoscopy. Tissue confirmation is particularly important when nodal findings would change treatment intent; enlarged or PET-positive nodes are not automatically malignant. (cancer.gov)

Small-cell lung cancer also uses the treatment-oriented distinction between limited-stage and extensive-stage disease. Limited-stage disease is confined to thoracic and regional nodal sites that can be encompassed within a tolerable thoracic radiotherapy field. Extensive-stage disease exceeds this distribution; any M1 disease, including a malignant pleural effusion, is extensive-stage. Limited-stage disease broadly overlaps TNM stages I–III with M0, but bulky or widely distributed intrathoracic disease may not fit a tolerable radiation field despite lacking distant metastases. TNM therefore supplies anatomical detail that the two-category system omits, distinguishing, for example, a small node-negative tumor from extensive mediastinal nodal involvement within limited-stage disease. (cancer.gov)

Screening and early detection

Screening examines people without symptoms to identify otherwise unsuspected cancer; investigation of symptoms or management of a nodule found incidentally on unrelated imaging follows a diagnostic pathway rather than a screening pathway. Low-dose computed tomography (LDCT) produces cross-sectional lung images using less radiation than conventional diagnostic CT, generally without intravenous contrast. It detects small nodules but does not itself establish a cancer diagnosis. Screening protocols use nodule size, appearance, and growth to distinguish findings requiring routine screening, short-interval imaging, or diagnostic evaluation. Chest radiography and sputum cytology have not demonstrated a lung-cancer mortality benefit sufficient to support their use as screening alternatives. (cancer.org)

The US National Lung Screening Trial (NLST) enrolled 53,454 people aged 55–74 with at least 30 pack-years of smoking exposure, including former smokers who had quit within 15 years. Participants were assigned to three annual LDCT examinations or chest radiographs. Results published in 2011 showed lung-cancer death rates of 247 versus 309 per 100,000 person-years: a 20.0% relative reduction, with a 95% confidence interval of 6.8–26.7%. The absolute difference was approximately three fewer lung-cancer deaths per 1,000 participants over an average 6.5 years of follow-up. These results established a mortality benefit in a defined high-risk population, rather than merely demonstrating that CT finds more early-stage tumors. (pubmed.ncbi.nlm.nih.gov)

The Dutch–Belgian NELSON randomized trial, reported by Harry de Koning and colleagues in 2020, assigned 13,195 men and 2,594 women aged 50–74 to volume-based LDCT screening or no screening. Examinations occurred at baseline and years 1, 3, and 5.5; nodule volume and growth informed subsequent assessment. In the primary male analysis, lung-cancer mortality at ten years was 2.50 versus 3.30 deaths per 1,000 person-years, with a rate ratio of 0.76 (95% confidence interval, 0.61–0.94). The smaller female subgroup had a rate ratio of 0.67, but its confidence interval, 0.38–1.14, included no difference. (pubmed.ncbi.nlm.nih.gov)

Eligibility criteria differ between programs and guideline bodies. The US Preventive Services Task Force’s March 9, 2021 recommendation specifies annual LDCT for adults aged 50–80 with at least 20 pack-years who currently smoke or quit within 15 years. A pack-year equals one pack daily for one year; two packs daily for ten years therefore constitute 20 pack-years. The American Cancer Society’s November 1, 2023 update uses the same age and exposure thresholds but removes the years-since-quitting restriction. Both approaches account for whether serious illness limits life expectancy or the ability to undergo curative treatment. England’s 2025 screening protocol targets current or former smokers aged 55–74 and applies multivariable risk thresholds: at least 1.51% six-year risk using PLCOm2012 or 2.5% five-year risk using LLPv2. These models incorporate factors beyond smoking exposure, including family history and respiratory disease. (uspreventiveservicestaskforce.org)

A false-positive result suggests cancer when none is ultimately found. Under NLST’s original thresholds, 24.2% of LDCT examinations were positive across three rounds, and 96.4% of positive results were false positives. Most were resolved through imaging, but some prompted biopsy or surgery, with associated complications. More selective nodule-classification systems can reduce false positives. Incidental findings, including emphysema, coronary calcification, and abnormalities outside the lungs, may generate additional investigations. Radiation exposure also accumulates through repeated screening and follow-up: the mean effective dose of an NLST LDCT examination was approximately 1.4 mSv. (pubmed.ncbi.nlm.nih.gov)

Overdiagnosis is distinct from a false positive: the detected cancer is real but would never have caused symptoms or death during the person’s lifetime. Estimates depend strongly on follow-up; NLST’s estimated proportion of overdiagnosed screen-detected cancers fell from approximately 18% to 3% with extended observation. Lead-time bias makes survival measured from diagnosis appear longer simply because diagnosis occurs earlier, even if death is unchanged. Length bias arises because screening preferentially detects slower-growing tumors with longer detectable preclinical phases. Consequently, longer survival after a screen-detected diagnosis is not, by itself, evidence of benefit; randomized comparisons of lung-cancer mortality address these interpretive problems. (cancer.gov)

Treatment planning and local therapies

Treatment planning distinguishes resectability, whether the tumor can be completely removed, from operability, whether the patient can tolerate the proposed operation. Multidisciplinary assessment integrates thoracic surgery, respiratory medicine, medical and radiation oncology, radiology, and pathology. Decisions incorporate anatomical stage, performance status—the ability to undertake daily activities—comorbidities, and patient preferences. Cardiopulmonary assessment includes cardiovascular evaluation, spirometry measuring forced expiratory volume in one second, and carbon-monoxide diffusing capacity; predicted postoperative values estimate the reserve remaining after resection, with exercise testing used when indicated. Localized non-small-cell lung cancer (NSCLC) may receive treatment with curative intent, including some medically inoperable tumors treated with radiation. In advanced disease, local treatment may instead control particular lesions or relieve symptoms. (ncbi.nlm.nih.gov)

Surgical procedures differ in the amount and anatomical organization of tissue removed. Lobectomy removes one lung lobe; segmentectomy removes an anatomical bronchopulmonary segment; wedge resection removes a nonanatomical portion containing the tumor and surrounding tissue. Pneumonectomy removes an entire lung, whereas sleeve resection removes an involved airway segment and reconstructs the bronchus, potentially preserving functioning lung. Resection includes assessment of hilar and mediastinal lymph nodes, through systematic sampling or dissection, to establish pathological stage and guide subsequent treatment. Video-assisted thoracoscopic and robotic-assisted approaches perform resections through small incisions rather than a conventional thoracotomy; the randomized VIOLET trial reported better early physical recovery after video-assisted lobectomy than after open surgery. (cancer.gov)

Lobectomy remains an important operation, but selected small peripheral tumors can receive lung-sparing resection. In CALGB/Alliance 140503, published in 2023, Nasser Altorki and colleagues randomized 697 patients with peripheral NSCLC measuring no more than 2 cm after intraoperative confirmation of node-negative disease. Sublobar resection, comprising segmentectomy or wedge resection, was noninferior to lobectomy for disease-free survival: five-year estimates were 63.6% and 64.1%, respectively. These findings apply to the trial’s carefully selected population, rather than establishing interchangeable operations for larger, central, or node-positive tumors. (pubmed.ncbi.nlm.nih.gov)

Thoracic radiotherapy directs radiation toward the tumor while limiting exposure of normal lung, heart, esophagus, and spinal cord. Conventional fractionation divides treatment into small daily doses; a widely used definitive chemoradiation schedule for unresectable stage III NSCLC is 60 Gy in 30 fractions. By contrast, stereotactic body radiotherapy (SBRT) delivers highly conformal, larger doses in a short course, commonly three to five treatments, and is an established curative-intent option for medically inoperable, early-stage, node-negative disease. Tumor proximity to major airways affects dose and fractionation because central lesions carry greater toxicity risks. Shorter palliative courses can relieve thoracic pain, bleeding, or obstruction without attempting eradication of all disease. (pmc.ncbi.nlm.nih.gov)

For resectable NSCLC, perioperative therapy addresses disease beyond the surgical field: neoadjuvant treatment precedes surgery, while adjuvant treatment follows it. Platinum-based chemotherapy is established for many fit patients with resected stage II–III disease; selected tumors also qualify for biomarker-directed adjuvant treatment or immunotherapy. On October 16, 2023, the US Food and Drug Administration approved pembrolizumab with platinum-containing chemotherapy before surgery, followed by pembrolizumab afterward, for resectable NSCLC with tumors at least 4 cm or positive nodes. Selected resectable stage III cases require coordinated multimodality planning; superior sulcus tumors provide an example in which chemoradiation may precede resection. (cancer.gov)

Unresectable stage III disease is generally treated with definitive combined chemoradiation rather than planned surgery. Concurrent treatment provides better survival than sequential chemotherapy followed by radiation in appropriately fit populations, but causes more toxicity; sequential treatment remains an option when concurrent treatment is unsuitable. Consolidation treatment follows chemoradiation when disease has not progressed: PACIFIC established durvalumab for eligible patients, with treatment lasting up to 12 months. Molecular findings can alter this pathway. On September 25, 2024, the FDA approved osimertinib after concurrent or sequential platinum-based chemoradiation for unresectable stage III NSCLC carrying an EGFR exon 19 deletion or exon 21 L858R mutation. (cancer.gov)

Systemic treatment of non-small-cell lung cancer

For metastatic or recurrent non-small-cell lung cancer (NSCLC), systemic treatment is selected according to histology, actionable molecular alterations, PD-L1 expression, previous treatment, and functional status. Cytotoxic chemotherapy commonly combines cisplatin or carboplatin with a second drug. Platinum compounds damage DNA through cross-linking; partner agents interfere with nucleotide metabolism or microtubule function. Pemetrexed-containing combinations are used for nonsquamous tumors, whereas squamous tumors commonly receive gemcitabine, paclitaxel, or nanoparticle albumin-bound paclitaxel with platinum. This distinction reflects clinical evidence rather than interchangeable drug preferences: in a randomized comparison, median overall survival among patients with adenocarcinoma was 12.6 months with cisplatin–pemetrexed versus 10.9 months with cisplatin–gemcitabine, while the corresponding results in squamous carcinoma favored gemcitabine, 10.8 versus 9.4 months. (cancer.gov)

Molecularly targeted therapy interrupts signaling on which a molecularly defined tumor depends. Osimertinib, an EGFR tyrosine kinase inhibitor, is used for tumors carrying EGFR exon 19 deletions or the exon 21 L858R substitution, either alone or with platinum–pemetrexed. In the 557-patient FLAURA2 randomized trial, published in 2023, investigator-assessed median progression-free survival was 25.5 months with the combination versus 16.7 months with osimertinib alone; severe adverse events were more frequent with combination treatment. Another established first-line option for these alterations is lazertinib plus amivantamab, a bispecific EGFR–MET antibody, approved in the United States on August 19, 2024. EGFR exon 20 insertions require distinct treatment strategies and should not be grouped indiscriminately with these common sensitizing mutations. (nejm.org)

ALK-rearranged tumors can receive ALK inhibitors such as alectinib or lorlatinib; activity against intracranial disease is an important differentiating feature. The CROWN trial, reported by Alice Shaw and colleagues in 2020, compared first-line lorlatinib with crizotinib and demonstrated superior progression-free survival and intracranial response with lorlatinib. KRAS-directed treatment is likewise alteration-specific: sotorasib and adagrasib target KRAS G12C rather than KRAS mutations generally. Their United States indications cover locally advanced or metastatic KRAS G12C-positive NSCLC after at least one previous systemic treatment. Adagrasib received accelerated approval for this indication on December 12, 2022; such approval is distinct from an unrestricted indication for every tumor carrying a KRAS alteration. (nejm.org)

Immune checkpoint inhibitors restore antitumor immune activity by blocking inhibitory signaling, including the interaction between PD-1 on T cells and PD-L1. Pembrolizumab monotherapy is an established option for selected tumors expressing PD-L1; its United States first-line indication includes a tumor proportion score of at least 1% and excludes EGFR or ALK genomic aberrations. Evidence for monotherapy is particularly strong in the high-expression group, defined as at least 50%. Chemotherapy–immunotherapy combinations do not require positive PD-L1 expression: KEYNOTE-189 evaluated pembrolizumab with platinum–pemetrexed in metastatic nonsquamous NSCLC without sensitizing EGFR or ALK alterations, while KEYNOTE-407 supported pembrolizumab with carboplatin and paclitaxel or albumin-bound paclitaxel in squamous disease. PD-L1 is therefore a predictive biomarker, not a universal gatekeeper for all immunotherapy regimens. (cancer.gov)

Maintenance treatment continues disease control after initial therapy rather than waiting for progression. After approximately four platinum-based induction cycles, nonsquamous disease may continue with pemetrexed, with pembrolizumab also continued when included in the initial regimen; the platinum component is usually discontinued. At progression, subsequent treatment depends on prior exposure and any remaining molecularly matched options. Established cytotoxic choices include docetaxel, alone or with ramucirumab, and pemetrexed when appropriate and not previously used. Molecular reassessment can identify eligibility for another targeted agent. Novel resistance-directed combinations and experimental drugs remain clinical-trial approaches unless supported by an established indication; activity observed in an early-phase study does not by itself establish superiority over available treatment. (cancer.gov)

Treatment of small-cell lung cancer

Limited-stage small-cell lung cancer (SCLC) is generally treated with curative-intent platinum–etoposide chemotherapy and concurrent thoracic radiotherapy. Cisplatin is the preferred platinum agent; carboplatin is an alternative when comorbidities make cisplatin unsuitable. Thoracic irradiation usually starts during the first or second chemotherapy cycle. An established schedule delivers 45 Gy in 30 twice-daily fractions over three weeks; once-daily schedules provide alternatives. Sequential chemotherapy and radiotherapy are used when concurrent treatment is unsuitable. Surgery has a restricted role, principally in carefully staged T1–2N0M0 disease: pathological mediastinal assessment precedes resection, systematic lymph-node dissection accompanies it, and postoperative chemotherapy remains necessary. Positive margins or mediastinal nodal involvement can additionally warrant postoperative irradiation. (pmc.ncbi.nlm.nih.gov)

For limited-stage disease that has not progressed after concurrent platinum-based chemoradiation, durvalumab provides an evidence-supported consolidation treatment. This immunotherapy blocks PD-L1, interrupting an immune-checkpoint pathway that suppresses antitumor T-cell activity. In the phase III ADRIATIC trial, median overall survival was 55.9 months with durvalumab versus 33.4 months with placebo; median progression-free survival was 16.6 versus 9.2 months. These estimates concern patients entering the trial after chemoradiation without progression, rather than all patients diagnosed with limited-stage SCLC. The US Food and Drug Administration (FDA) approved this indication on December 4, 2024, with treatment continuing until progression, unacceptable toxicity, or a maximum of 24 months. (cancer.gov)

Extensive-stage disease is commonly treated with platinum–etoposide plus either atezolizumab or durvalumab, followed by maintenance immunotherapy. In IMpower133, atezolizumab plus carboplatin–etoposide produced median overall survival of 12.3 months versus 10.3 months with chemotherapy alone; CASPIAN likewise demonstrated a survival benefit from adding durvalumab. Consolidative thoracic irradiation has a role in selected responders with residual chest disease, although its evidence base largely predates routine chemo-immunotherapy. Maintenance treatment expanded in the United States on October 2, 2025, when the FDA approved lurbinectedin plus atezolizumab after nonprogression on atezolizumab–carboplatin–etoposide induction. In IMforte, median overall survival measured from maintenance randomization—not initial diagnosis—was 13.2 months with the combination versus 10.6 months with atezolizumab alone. (cancer.gov)

Prophylactic cranial irradiation (PCI) treats patients without detected brain metastases to reduce subsequent intracranial relapse. It remains an established option for responding stage II–III limited-stage disease, commonly at 25 Gy in 10 fractions. Brain MRI before PCI excludes already established metastases, which require therapeutic rather than prophylactic treatment. Cognitive toxicity is an important consideration, particularly with advanced age, impaired baseline cognition, or substantial comorbidity. In extensive-stage disease, scheduled MRI surveillance is an alternative in appropriate clinical contexts. Toshiaki Takahashi and colleagues’ 2017 randomized trial enrolled 224 chemotherapy responders with negative brain MRI: PCI reduced brain metastases but did not improve overall survival compared with surveillance. MRI was performed every three months during the first year and again at 18 and 24 months. (pmc.ncbi.nlm.nih.gov)

At recurrence, the interval between completing chemotherapy and relapse helps predict responsiveness to further cytotoxic treatment. A commonly used research definition classifies relapse more than 90 days after treatment as chemotherapy-sensitive; earlier relapse or failure to respond indicates resistant disease. Longer intervals can support reuse of platinum–etoposide, with cumulative toxicity also influencing selection. Subsequent options include oral or intravenous topotecan and lurbinectedin, a selective inhibitor of oncogenic transcription. These agents have distinct evidence bases and toxicity profiles; relapse timing is not an absolute biological boundary. (cancer.gov)

Tarlatamab is a bispecific T-cell engager that binds DLL3 on tumor cells and CD3 on T cells, bringing immune effector cells into contact with the malignancy. In the randomized DeLLphi-304 trial, 509 patients whose disease progressed after platinum-based chemotherapy received tarlatamab or investigator-selected chemotherapy: median overall survival was 13.6 versus 8.3 months. Following accelerated approval in 2024, the FDA granted traditional approval on November 19, 2025, for extensive-stage SCLC progressing on or after platinum-based chemotherapy. Its boxed warning identifies potentially life-threatening cytokine-release syndrome and neurological toxicity, including immune effector cell-associated neurotoxicity syndrome. (cancer.gov)

Supportive care, complications, and survivorship

Palliative care addresses symptoms, psychological distress, practical difficulties, and communication about treatment goals alongside cancer-directed treatment; it is not restricted to the final weeks of life. Hospice care is a distinct model in which comfort rather than cure is the principal goal. Evidence for early integration includes a 2010 randomized controlled trial by Jennifer S. Temel and colleagues involving 151 patients with newly diagnosed metastatic non-small-cell lung cancer at Massachusetts General Hospital. At 12 weeks, patients receiving early palliative care alongside oncology care had higher lung-cancer-specific quality-of-life scores than those receiving oncology care alone, 98.0 versus 91.5, and fewer had depressive symptoms, 16% versus 38%. These findings concern a defined advanced-disease population rather than every lung-cancer setting. (cancer.gov)

Symptom management begins with assessment of severity, functional impact, and potentially reversible causes. Pain management can combine non-opioid analgesics, opioids, and additional medicines for nerve-related pain; palliative radiotherapy can relieve pain from bone metastases by reducing local tumor burden. Breathlessness may reflect airway obstruction, pleural fluid, infection, anemia, pulmonary embolism, underlying lung disease, or treatment toxicity, often in combination. Management therefore encompasses cause-directed interventions, such as pleural drainage, as well as breathing strategies, airflow from a fan, and pharmacological symptom relief. Oxygen is principally relevant when oxygen levels are reduced, rather than as a universal treatment for breathlessness. (cancer.gov)

Fatigue requires assessment of contributing factors such as anemia, sleep disturbance, pain, depression, and reduced physical activity; management includes appropriately adapted exercise and psychosocial interventions. Nutritional care addresses inadequate intake, nausea, altered taste, appetite loss, and swallowing difficulties, with dietitians assessing energy and protein needs. Cancer cachexia differs from simple undernutrition: inflammation and metabolic changes contribute to skeletal-muscle and fat loss, and nutritional support alone cannot reverse the syndrome. Psychological care addresses anxiety, depression, fear of recurrence, and difficulties adjusting to changes in independence or family roles. Counseling and social-work support also help patients and families manage practical burdens. (cancer.gov)

Treatment complications can interrupt therapy and persist into survivorship. Chemotherapy can suppress bone-marrow blood-cell production: neutropenia increases infection risk, anemia contributes to fatigue and breathlessness, and thrombocytopenia increases bleeding risk. Clinical management includes blood-count monitoring and, according to severity and treatment context, treatment modification, growth-factor support, or transfusion. Neurotoxic drugs, including platinum compounds and taxanes, can cause peripheral neuropathy, producing numbness, tingling, pain, weakness, or impaired balance. These deficits can interfere with walking and daily tasks, making functional assessment and rehabilitation relevant beyond completion of chemotherapy. (cancer.gov)

Pneumonitis is inflammatory lung injury that can follow thoracic irradiation or systemic treatment; radiation-related injury can also leave pulmonary fibrosis. New cough, breathlessness, or imaging abnormalities require distinction from infection and cancer progression. Immune-checkpoint inhibitors can provoke inflammation in healthy tissues, including pneumonitis, colitis, hepatitis, thyroid or pituitary dysfunction, and less commonly myocarditis or neurological inflammation. Such adverse effects may arise during treatment or after it has stopped, extending toxicity surveillance beyond the last dose. (cancer.gov)

Rehabilitation addresses strength, endurance, mobility, and the ability to perform everyday activities, with physical and occupational therapy adapted to persistent symptoms and functional limitations. Caregiver support includes information, emotional support, and help coordinating care; caregivers may also experience distress as patients lose weight or physical independence. Post-treatment follow-up evaluates recurrence or a second primary cancer while also identifying persistent and delayed treatment effects. A survivorship care plan records the diagnosis and treatments, anticipated late effects, surveillance arrangements, and responsibilities of oncology and primary-care services. Survivorship includes both people without detectable disease and those living with cancer under continuing treatment. (cancercontrol.cancer.gov)

Prognosis, recurrence, and treatment resistance

Prognosis depends strongly on disease stage, but also on histological subtype, molecular characteristics, functional status, and response to treatment. In non-small-cell lung cancer (NSCLC), increasing stage, vascular invasion, and greater lymph-node involvement are associated with poorer outcomes. Poor performance status—reduced ability to undertake ordinary activities—and weight loss exceeding 10% are adverse prognostic factors in inoperable disease. Molecular alterations can affect outcomes partly by determining sensitivity to particular treatments: an actionable mutation is therefore not simply a marker of intrinsically favorable tumor behavior. A biomarker that predicts benefit from a specific drug is distinct from a prognostic factor associated with outcomes irrespective of treatment. Tumor shrinkage and the duration of disease control provide additional information after treatment begins. (cancer.gov)

Survival measures answer different questions. Relative survival compares observed survival among patients with expected survival in a comparable population without cancer, estimating excess mortality without requiring the recorded cause of each death. Overall survival measures survival until death from any cause, with the starting point specified—for example, diagnosis or randomization in a trial. Progression-free survival measures time until documented disease progression or death, generally from randomization; patients may still have detectable cancer throughout that interval. It is not synonymous with cure or freedom from recurrence after definitive treatment. Differences in assessment schedules and definitions of progression can affect progression-free survival, and an improvement in this endpoint does not necessarily establish an improvement in overall survival. (surveillance.cancer.gov)

United States SEER registry estimates, reproduced by the American Cancer Society, illustrate the influence of stage and histology. Among people diagnosed with NSCLC during 2015–2021, five-year relative survival was 67% for localized disease, 40% for regional disease, and 12% for distant disease, with 32% across all stages. For small-cell lung cancer diagnosed during 2012–2018, the corresponding estimates were 34%, 20%, and 4%, with 9% overall. Here, localized means confined to the lung; regional means spread to nearby structures or lymph nodes; and distant means spread to distant sites. These SEER summary-stage categories are not equivalent to individual TNM stage groups or the limited/extensive classification of small-cell disease. The figures describe stage at initial diagnosis, not survival after recurrence. Their different diagnosis periods also limit direct comparison, and historical population averages do not incorporate all benefits of subsequently introduced treatments. (cancer.org)

Recurrence is the reappearance of the original cancer after a period in which it was undetectable; it may be local, regional, or distant. A second primary lung cancer arises independently rather than representing spread from the first tumor. A new pulmonary lesion cannot reliably be assigned to either category solely from its location or the elapsed time. Reassessment integrates imaging, detailed pathological comparison, and, when informative, molecular profiles from the original and new tumors. Different histological types strongly support separate primaries, whereas matching histology alone does not establish a shared origin. This distinction changes staging and treatment intent: an independent localized primary may remain amenable to definitive local treatment. Repeat biopsy in recurrent or progressing disease can also reveal changed histology or molecular targets. (pubmed.ncbi.nlm.nih.gov)

Intrinsic resistance exists before treatment, whereas acquired resistance becomes evident after initial sensitivity. Treatment can select pre-existing resistant cell populations, while surviving cells may acquire additional changes that permit growth despite therapy. Mechanisms documented in EGFR-mutant NSCLC include alterations of the drug target, such as EGFR C797S during osimertinib treatment, and amplification of MET, which enables alternative growth signaling. Histological transformation is another route: in Lecia Sequist and colleagues’ 2011 study of biopsies from 37 patients with EGFR-mutant NSCLC resistant to EGFR inhibitors, five tumors had transformed into small-cell carcinoma while retaining their original EGFR mutations. Such findings demonstrate tumor evolution in sampled patient cohorts, not a universal sequence. Resistance mechanisms may coexist, differ between tumor sites, or remain unidentified; results from laboratory models alone do not establish their frequency or clinical importance in patients. (cancer.gov)

Prevention and population-level cancer control

Preventing smoking initiation and promoting smoking cessation are the principal measures for preventing tobacco-related lung cancer. Avoiding smoking prevents cumulative exposure to tobacco carcinogens; stopping smoking reduces risk progressively, although previous exposure continues to influence subsequent risk. The US National Cancer Institute reports a 30–60% reduction in lung cancer risk after ten years of cessation, with the magnitude depending on smoking history and time since quitting. Cessation services use behavioral counseling and pharmacological treatment, including nicotine replacement, to improve sustained abstinence. Secondhand smoke also causes lung cancer, making protection of people who do not smoke a separate prevention objective rather than merely an extension of cessation programs. (cancer.gov)

Population-level tobacco control combines interventions that alter the price, availability, promotion, and social environment of tobacco use. The World Health Organization’s MPOWER framework comprises monitoring tobacco use, protecting people from smoke, offering cessation assistance, warning about tobacco’s dangers, enforcing advertising and sponsorship bans, and raising tobacco taxes. Taxes reduce consumption and discourage initiation, particularly among young people; advertising restrictions reduce promotional exposure, while smoke-free legislation protects people in indoor workplaces, public transport, and public venues. These measures operate together rather than as isolated educational campaigns. In Brazil, which implemented all six MPOWER measures at WHO’s highest implementation level, smoking prevalence fell from 22.4% in 2003 to 12.6% in 2019. This observed population change illustrates comprehensive program implementation, but does not isolate the contribution of any single policy. (who.int)

Occupational prevention reduces exposure at its source. WHO identifies discontinuing all forms of asbestos and substituting lower-hazard materials as the most effective means of preventing asbestos-related disease; preventing exposure during maintenance and removal of existing asbestos-containing materials remains necessary. For respirable crystalline silica, engineering controls include wet drilling, enclosed operator cabs, and local exhaust ventilation. The latter captures dust where cutting, crushing, or grinding generates it, before it disperses into workplace air. Exposure monitoring provides a basis for evaluating controls, while respiratory protection supplements engineering measures where residual exposure remains. These protections address workplace hazards independently of workers’ smoking histories. (who.int)

Residential radon control combines national testing protocols, building requirements, and remediation programs. WHO proposes an annual-average residential reference level of $100\ \mathrm{Bq/m^3}$; where national conditions prevent achieving this, the reference level should not exceed $300\ \mathrm{Bq/m^3}$. Because concentrations fluctuate, measurements lasting at least three months better estimate annual exposure than brief measurements. Mitigation includes under-floor ventilation, radon sump systems, sealing entry routes, and preventing basement air from entering occupied rooms. Building codes can incorporate preventive features during construction, while financial support can facilitate remediation of existing buildings. These interventions reduce inhalation of radioactive decay products that deposit in the airways and damage DNA. (who.int)

Control of air pollution requires measures across transport, energy, industry, housing, and waste management. Examples include reducing industrial emissions, cleaner vehicles and fuels, public transport investment, and access to clean household energy for cooking and heating. Such policies address exposures that individuals cannot readily control and reduce pollution-related lung cancer alongside other cardiopulmonary diseases. WHO’s population-control approach therefore extends beyond tobacco to both ambient emissions and household combustion sources. (who.int)

Supplement-based chemoprevention has not established a preventive role, and high-dose beta-carotene caused harm in major randomized trials. The Finnish Alpha-Tocopherol, Beta-Carotene Cancer Prevention trial, reported in 1994, enrolled 29,133 male smokers aged 50–69. Beta-carotene at 20 mg daily increased lung cancer incidence by 18% relative to participants not receiving it; vitamin E did not reduce incidence. The US Beta-Carotene and Retinol Efficacy Trial, reported in 1996, enrolled 18,314 smokers, former smokers, and asbestos-exposed workers. Its combination of 30 mg beta-carotene and 25,000 IU retinyl palmitate daily increased lung cancer incidence by 28% and all-cause mortality by 17%, prompting early termination. These findings concern pharmacological-dose supplements in the studied populations, not ordinary dietary intake of carotenoid-containing foods. (cancer.gov)

Access, inequalities, and health-system organization

Geographical and socioeconomic inequalities affect lung-cancer diagnosis, receipt of treatment, and outcomes. The social determinants of health operate throughout this pathway, rather than solely through differences in exposure to carcinogens: disadvantaged populations may also have less access to timely investigation and effective treatment. Financing is an important constraint across countries. In a World Health Organization survey of 115 countries released in February 2024, only 39% reported including basic cancer management in publicly financed health-benefit packages available to all citizens, and 28% additionally covered palliative care, including general pain relief. These figures concern cancer services overall, not lung cancer specifically, but describe the financing environment in which lung-cancer care is delivered. (cancer-inequalities.iarc.who.int)

Differences also occur within countries with extensive medical infrastructure. A United States Medicare cohort study included 126,352 beneficiaries with newly diagnosed, non-metastatic lung cancer during 2016–2018. Cancer-directed surgery was recorded for 22.1% of metropolitan residents, compared with 18.7% of micropolitan residents, 17.5% of small-town residents, and 17.8% of isolated-rural residents. Non-metropolitan residence remained associated with lower surgical receipt after adjustment for age, sex, race or ethnicity, comorbidities, and local socioeconomic deprivation. Among surgical patients, median travel distances were 10.6 miles for metropolitan residents and 51.9 miles for small-town or rural residents; postoperative emergency-department visits were also more frequent outside metropolitan areas. Ninety-day mortality from diagnosis was 16.8% in metropolitan areas and 20.2% in isolated-rural areas. These observational findings document inequalities but do not establish that geography alone caused the outcome differences. (pmc.ncbi.nlm.nih.gov)

The diagnostic infrastructure includes tissue-sampling services, experienced pathology laboratories, and access to staging investigations such as computed tomography, positron-emission tomography, brain imaging, and mediastinal lymph-node sampling. Molecular and immunological biomarker testing forms a further link between diagnosis and treatment selection: identifying a potentially treatable alteration requires an adequate specimen, a validated assay, and a result available to the treating team. The National Cancer Institute’s treatment summary identifies tumor-genomic assessment and PD-L1 testing as critical before treatment selection for advanced non-small-cell disease. Thus, access to medication alone does not constitute access to molecularly selected care; laboratory and clinical services must be connected. (cancer.gov)

Treatment capacity likewise depends on personnel and sustained operating resources, not simply equipment purchases. Multidisciplinary pathways connect thoracic surgery, medical oncology, radiotherapy, and palliative care. Radiotherapy services require treatment-planning systems, dosimetry equipment, radiation oncologists, medical physicists, radiation therapists, nursing staff, and maintenance support. International Atomic Energy Agency planning guidance emphasizes preventive maintenance, written quality-assurance procedures, continuing staff training, and systematic follow-up of treatment outcomes. Coordinated treatment planning is particularly important when several modalities are delivered by different departments or institutions. (who.int)

Screening access depends on more than eligibility for low-dose CT. In a 2020 mixed-methods study led by Jenna Schiffelbein, 23 rural screening-eligible adults who were not up to date with screening participated in five focus groups. Reported barriers included lack of information about screening, absence of a clinician recommendation, and transportation difficulties. The small sample does not provide national prevalence estimates, but identifies concrete points at which access can fail. Screening programmes also require arrangements for investigating abnormal results and referral to treatment; a scan without this subsequent pathway is not a complete early-detection service. Continuity problems extend beyond diagnosis, as illustrated by the travel burden and postoperative emergency-care use in the Medicare cohort. These are service-delivery barriers, not evidence of individual responsibility for disease. (pubmed.ncbi.nlm.nih.gov)

Cancer registries provide the infrastructure for measuring these differences. Registries collect demographic characteristics, tumor site and histology, stage, treatment, vital status, and survival time from hospitals, laboratories, outpatient services, and other reporting sources. Individual identifiers support duplicate checking, while secure data management protects confidentiality. Population-based programmes such as the United States Surveillance, Epidemiology, and End Results programme combine cancer records with population data to examine incidence, stage distributions, and survival by geographical area and demographic group. This public-health surveillance supports service planning and evaluation, including identifying populations with persistently late diagnosis or unequal outcomes. (seer.cancer.gov)

Historical milestones and research directions

In 1950, two influential case–control studies linked cigarette smoking with lung cancer: Ernst Wynder and Evarts Graham reported findings in the United States, while Richard Doll and A. Bradford Hill published their British study in September. Comparing smoking histories in patients with lung cancer and controls provided evidence of an association, including greater risk with heavier consumption; subsequent prospective studies strengthened the causal interpretation. These findings became milestones in epidemiology, rather than evidence from experiments assigning people to smoke. On January 11, 1964, US Surgeon General Luther L. Terry released Smoking and Health. Drawing on more than 7,000 publications, its advisory committee concluded that cigarette smoking caused lung cancer in men and was a probable cause in women—the latter wording reflecting the evidence available at that time. (cancer.gov)

Molecularly selected treatment developed from the recognition that histologically similar tumors could have different therapeutic vulnerabilities. In 2004, studies including work by J. Guillermo Paez and colleagues associated somatic EGFR mutations with sensitivity to gefitinib, an inhibitor of receptor tyrosine-kinase signaling. Gefitinib had received accelerated US approval in 2003; its 2015 approval for initial treatment of metastatic disease specifically required qualifying EGFR mutations, illustrating the shift toward predictive biomarkers. Another milestone came on March 4, 2015, when nivolumab received US approval for previously treated advanced squamous non-small-cell lung cancer. This immunotherapy blocks PD-1 on T cells, interrupting an inhibitory signal rather than directly inhibiting a tumor growth pathway. Its approval followed a randomized comparison with docetaxel involving 272 patients. (pubmed.ncbi.nlm.nih.gov)

Screening likewise progressed through mortality trials rather than the observation that imaging found smaller tumors. The National Lung Screening Trial enrolled 53,454 high-risk participants in 2002–2004 and compared three annual low-dose CT examinations with chest radiography. Its 2011 report found a 20.0% relative reduction in lung-cancer mortality. The Dutch–Belgian NELSON trial, reported in 2020, compared volume-based CT screening with no screening and found a lung-cancer mortality rate ratio of 0.76 among men at ten years. These randomized controlled trials established that particular screening programs could reduce deaths, not merely advance the date of diagnosis. (pubmed.ncbi.nlm.nih.gov)

Earlier-detection research includes blood and sputum markers intended to complement imaging. Circulating tumor DNA (ctDNA)—tumor-derived DNA fragments in blood—has established uses in identifying certain treatment-relevant mutations: the FDA authorized a plasma EGFR companion diagnostic in 2016. This differs from detecting molecular residual disease after treatment intended to cure. A 2023 TRACERx analysis tracked a median of 200 tumor mutations across 1,069 plasma samples from 197 patients; postoperative detection identified some patients who later relapsed, but did not identify every relapse. Detection therefore provides prognostic information without, by itself, proving that changing treatment improves outcomes. Trials such as MRD-PORT investigate whether postoperative ctDNA can guide treatment in stage II–III disease. Blood- or sputum-based early-detection tests remain a separate research question from mutation testing in established cancer. (cancer.gov)

Resistance research combines repeated tissue sampling, longitudinal blood measurements, and experimental models. TRACERx compares genetically distinct regions of primary tumors with subsequent metastases to reconstruct clonal evolution; these observational reconstructions generate hypotheses about dissemination rather than establish the efficacy of a treatment. Patient-derived organoids and other cultures provide systems for testing mechanisms and candidate drugs, with molecular comparison against the original tumor helping characterize model fidelity. Clinical benefit still requires evaluation in patients. Representative enrollment also matters: Pragmatica-Lung, launched in March 2023, simplified trial procedures and permitted participation by patients with poorer functional status than many conventional trials, addressing the gap between selected study populations and people treated in routine practice. (nature.com)

References

1. Definition of lung cancer - NCI Dictionary of Cancer Termscancer.gov
2. What Is Cancer? - NCIcancer.gov
3. Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version - NCIcancer.gov
4. Bronchi, Bronchial Tree, & Lungs - SEER Trainingtraining.seer.cancer.gov
5. What Is Mesothelioma? - NCIcancer.gov
6. Definition of bronchogenic carcinoma - NCI Dictionary of Cancer Termscancer.gov
7. Lymph Nodes - SEER Trainingtraining.seer.cancer.gov
8. Thoracic Tumourspublications.iarc.fr
9. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinomapmc.ncbi.nlm.nih.gov
10. Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Versioncancer.gov
11. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indicesnature.com
12. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinomapubmed.ncbi.nlm.nih.gov
13. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committeepmc.ncbi.nlm.nih.gov
14. New report on global cancer burden in 2022 by world region and human development leveliarc.who.int
15. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesdr2pp.oss.ns-svc.cn
16. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCANdoi.org
17. Lung and Bronchus Cancer — Cancer Stat Factsseer.cancer.gov
18. Global lung cancer incidence according to subtype: new study highlights rising adenocarcinoma rates linked to air pollutioniarc.who.int
19. Lung Cancer Among People Who Never Smokedcdc.gov
20. Saving Lives from Lung Cancer: Seeing Past the Smokecdc.gov
21. Harms of Cigarette Smoking and Health Benefits of Quittingcancer.gov
22. Risk Factors: Tobaccocancer.gov
23. Lung Cancer Prevention (PDQ®)–Health Professional Versioncancer.gov
24. Glossary for Registrars: Pack yearseer.cancer.gov
25. Radonwho.int
26. Asbestos Exposure and Cancer Riskcancer.gov
27. Asbestos—Cancer-Causing Substancescancer.gov
28. Lung Cancer Prevention (PDQ®)–Patient Versioncancer.gov
29. Diesel and Gasoline Engine Exhausts and Some Nitroarenespublications.iarc.who.int
30. Outdoor air pollution a leading environmental cause of cancer deathswho.int
31. Does household use of biomass fuel cause lung cancer? A systematic review and evaluation of the evidence for the GBD 2010 studyiarc.who.int
32. Air pollution and canceriarc.who.int
33. Mutational signatures associated with tobacco smoking in human cancerpmc.ncbi.nlm.nih.gov
34. Comprehensive molecular profiling of lung adenocarcinomanature.com
35. Comprehensive genomic profiles of small cell lung cancernature.com
36. SHP(ing) out oncogenic KRAS towards therapeuticscancer.gov
37. Biomarker Testing for Cancer Treatmentcancer.gov
38. Club cells employ regeneration mechanisms during lung tumorigenesisnature.com
39. The evolution of lung cancer and impact of subclonal selection in TRACERxnature.com
40. Neoantigen-directed immune escape in lung cancer evolutionnature.com
41. Neoantigen directed immune escape in lung cancer evolutiondiscovery.ucl.ac.uk
42. Immune Checkpoint Inhibitorscancer.gov
43. Lung Cancer Signs & Symptoms | American Cancer Societycancer.org
44. Cardiopulmonary Syndromes (PDQ®) - NCIcancer.gov
45. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncologypmc.ncbi.nlm.nih.gov
46. Lambert-Eaton myasthenic syndrome: MedlinePlus Medical Encyclopediamedlineplus.gov
47. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancerpubmed.ncbi.nlm.nih.gov
48. How to Detect Lung Cancer | Lung Cancer Tests | American Cancer Societycancer.org
49. Diagnosis and staging | Lung cancer: diagnosis and management | Guidance | NICEnice.org.uk
50. Lung cancer: diagnosis and managementnice.org.uk
51. Lung Biopsy | Chest Nodule Biopsy | Pleural Membrane Biopsyradiologyinfo.org
52. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancerpmc.ncbi.nlm.nih.gov
53. IASLC Lung Cancer News / April 2019iaslc.org
54. BTS guidelines for the investigation and management of pulmonary nodulesbrit-thoracic.org.uk
55. Tumor Markers - NCIcancer.gov
56. Molecular Testing Guideline For The Selection Of Lung Cancer Patients For Treatment With TKI - CAPcap.org
57. Guideline For Molecular Testing In Lung Cancer Revised, Updated - CAPcap.org
58. Premarket Approval (PMA): PD-L1 IHC 22C3 pharmDxaccessdata.fda.gov
59. IASLC Issues Consensus Updated Report on Liquid Biopsiesiaslc.org
60. Liquid Biopsy: Using Tumor DNA in Blood to Aid Cancer Care - NCIcancer.gov
61. IASLC Staging Project: Lung Cancer, Thymic Tumors, and Mesotheliomaiaslc.org
62. IASLC Staging Reference Cards, 9th Editioneducation.iaslc.org
63. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancerpubmed.ncbi.nlm.nih.gov
64. Metastatic Cancer: When Cancer Spreadscancer.gov
65. Non-small Cell Lung Cancer Stagescancer.org
66. Lung Cancer Screening (PDQ®) - NCIcancer.gov
67. Lung Cancer Early Detection | Lung Cancer Screening | American Cancer Societycancer.org
68. Reduced lung-cancer mortality with low-dose computed tomographic screening - PubMedpubmed.ncbi.nlm.nih.gov
69. National Lung Screening Trial: Questions and Answers - NCIcancer.gov
70. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial - PubMedpubmed.ncbi.nlm.nih.gov
71. Recommendation: Lung Cancer: Screening | United States Preventive Services Taskforceuspreventiveservicestaskforce.org
72. American Cancer Society Updates Lung Cancer Screening Guidelinepressroom.cancer.org
73. Diagnosis and management of lung cancer: recommendationsncbi.nlm.nih.gov
74. Physiologic evaluation of the patient with lung cancer being considered for resectional surgerypubmed.ncbi.nlm.nih.gov
75. Non-Small Cell Lung Cancer Treatment (PDQ®)–Patient Versioncancer.gov
76. Impact of video-assisted thoracoscopic lobectomy versus open lobectomy for lung cancer on recovery assessed using self-reported physical function: VIOLET RCTpubmed.ncbi.nlm.nih.gov
77. Robotic-assisted Versus Video-assisted Thoracoscopic Lobectomy: Short-term Results of a Randomized Clinical Trial (RVlob Trial)pubmed.ncbi.nlm.nih.gov
78. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancerpubmed.ncbi.nlm.nih.gov
79. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617)pmc.ncbi.nlm.nih.gov
80. FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancerfda.gov
81. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancerpubmed.ncbi.nlm.nih.gov
82. FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapyfda.gov
83. NSCLC locally advanced or metastatic cisplatin and pemetrexedeviq.org.au
84. FDA approves lazertinib with amivantamab-vmjw for non-small lung cancerfda.gov
85. Lazertinib multidisciplinary reviewaccessdata.fda.gov
86. Ongoing Cancer Accelerated Approvalsfda.gov
87. FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq and Krazatifda.gov
88. FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%)fda.gov
89. KEYTRUDA prescribing informationdailymed.nlm.nih.gov
90. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-uppmc.ncbi.nlm.nih.gov
91. Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guidelinepmc.ncbi.nlm.nih.gov
92. FDA approves durvalumab for limited-stage small cell lung cancerfda.gov
93. FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancerfda.gov
94. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trialpubmed.ncbi.nlm.nih.gov
95. FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancerfda.gov
96. Palliative Care in Cancer - NCIcancer.gov
97. Early palliative care for patients with metastatic non-small-cell lung cancerpubmed.ncbi.nlm.nih.gov
98. Cancer Pain - NCIcancer.gov
99. Fatigue (PDQ®) - NCIcancer.gov
100. Nutrition During Cancer Treatment - NCIcancer.gov
101. Cachexia and Cancer - NCIcancer.gov
102. Chemotherapy and You - NCIcancer.gov
103. Anemia and Cancer Treatment - NCIcancer.gov
104. Infection and Neutropenia and Cancer Treatment - NCIcancer.gov
105. Chemotherapy-Induced Peripheral Neuropathy: Clinical Trials Planning Meeting Executive Summarycancer.gov
106. Nerve Problems (Peripheral Neuropathy) and Cancer Treatment - NCIcancer.gov
107. Lung Cancer Survival Ratescancer.org
108. Measures of Cancer Survivalsurveillance.cancer.gov
109. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologicsfda.gov
110. Cancer Prognosiscancer.gov
111. The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancerpubmed.ncbi.nlm.nih.gov
112. Why Do Cancer Treatments Stop Working?cancer.gov
113. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancernature.com
114. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitorspmc.ncbi.nlm.nih.gov
115. Cancer Care Settings and Smoking Cessationcdc.gov
116. Health Promotionwho.int
117. MPOWERwho.int
118. MPOWER package of data-driven tobacco control measures helps protect up to 5 billion liveswho.int
119. Asbestoswho.int
120. Engineering Controls Database - Best Practices for Dust Control in Metal/Nonmetal Mining – Mineral Processing Operations – Local Exhaust Ventilation Systemscdc.gov
121. Preventing Silicosis and Deaths in Rock Drillersarchive.cdc.gov
122. A Guide to Respirators Used for Dust in Constructioncdc.gov
123. Ambient (outdoor) air pollutionwho.int
124. Cancer Inequalities: Social inequalitiescancer-inequalities.iarc.who.int
125. Global cancer burden growing, amidst mounting need for servicesiarc.who.int
126. Rural Disparities in Lung Cancer-Directed Surgery: A Medicare Cohort Studypmc.ncbi.nlm.nih.gov
127. Lung cancerwho.int
128. Planning National Radiotherapy Services: A Practical Toolconferences.iaea.org
129. Planning National Radiotherapy Services: A Practical Toolpub.iaea.org
130. Barriers, Facilitators, and Suggested Interventions for Lung Cancer Screening Among a Rural Screening-Eligible Populationpubmed.ncbi.nlm.nih.gov
131. Data Collection, Storage, & Managementseer.cancer.gov
132. Data Collectiontraining.seer.cancer.gov
133. SEER Data & Softwareseer.cancer.gov
134. What is a Cancer Registry?seer.cancer.gov
135. Milestones in Cancer Research and Discovery - NCIcancer.gov
136. Smoking and Carcinoma of the Lung: Preliminary Reportcsts.ua.edu
137. A History of the Surgeon General's Reports on Smoking and Healthcdc.gov
138. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapypubmed.ncbi.nlm.nih.gov
139. Gefitinib Approved for Some Lung Cancer Patients - NCIcancer.gov
140. FDA Approves First Immunotherapy Treatment for Lung Cancer - NCIcancer.gov
141. Advances in Lung Cancer Research - NCIcancer.gov
142. List of FDA-Authorized Companion Diagnostic Devices (In Vitro and Imaging Tools)fda.gov
143. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNAnature.com